{"transactions":[{"id":679711,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":114072,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":679710,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":24.5,"value":245000.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":679709,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":14.41,"value":144100.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":679708,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T00:05:06.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":4212,"price":24.5,"value":103194.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-359636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526359636/ownership.xml","form_type":"4"}},{"id":682827,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":22055,"kind":"person","name":"Tripuraneni Radhika","position":1,"cik":"0001761114","reported_name":"Tripuraneni Radhika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-18T21:34:08.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.21,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-355735","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526355735/ownership.xml","form_type":"4"}},{"id":682826,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":22055,"kind":"person","name":"Tripuraneni Radhika","position":1,"cik":"0001761114","reported_name":"Tripuraneni Radhika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-18T21:34:08.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":13.21,"value":528400.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001193125-26-355735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526355735/ownership.xml","form_type":"4"}},{"id":718209,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32923,"kind":"person","name":"CAIN CHRISTOPHER W.","position":1,"cik":"0001817733","reported_name":"CAIN CHRISTOPHER W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:27.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294561","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817733/000119312526294561/ownership.xml","form_type":"4"}},{"id":717279,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:26.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294560","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000119312526294560/ownership.xml","form_type":"4"}},{"id":717201,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32643,"kind":"person","name":"Moses Jennifer K.","position":1,"cik":"0001706667","reported_name":"Moses Jennifer K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:21.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294556","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526294556/ownership.xml","form_type":"4"}},{"id":718399,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:17.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000119312526294552/ownership.xml","form_type":"4"}},{"id":717196,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2224,"kind":"person","name":"Kiselak Tomas","position":1,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:07.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294547","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526294547/ownership.xml","form_type":"4"}},{"id":717663,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":18365,"kind":"person","name":"Morris Arlene","position":1,"cik":"0001362520","reported_name":"Morris Arlene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:06.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362520/000119312526294546/ownership.xml","form_type":"4"}},{"id":780420,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-13T20:31:15.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":1176470,"price":17,"value":19999990.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") and Fairmount Healthcare Fund II GP LLC (\"Fairmount GP II\") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":5090928,"source":{"system":"sec-edgar","filing":"0001104659-26-060294","document":"tm2614357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465926060294/tm2614357-1_4seq1.xml","form_type":"4"}},{"id":853109,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-09T23:42:53.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":3048,"price":30.19,"value":92019.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."}],"balance_after":13361,"source":{"system":"sec-edgar","filing":"0001193125-26-099014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526099014/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-04"}},{"id":853108,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-09T23:35:29.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1675,"price":30.19,"value":50568.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."}],"balance_after":3494,"source":{"system":"sec-edgar","filing":"0001193125-26-099008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526099008/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-04"}},{"id":853107,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-09T23:35:08.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":7408,"price":30.19,"value":223647.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."}],"balance_after":33349,"source":{"system":"sec-edgar","filing":"0001193125-26-099007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526099007/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-04"}},{"id":853833,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-09T19:49:36.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":2031,"price":30.19,"value":61315.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."}],"balance_after":7850,"source":{"system":"sec-edgar","filing":"0001193125-26-099023","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000119312526099023/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-04"}},{"id":860716,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":5169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":15510,"derivative":{"underlying":"Common Stock","underlying_shares":5169},"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860715,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":23850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":23850,"derivative":{"underlying":"Common Stock","underlying_shares":23850},"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860714,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":119300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":119300,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":119300},"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860713,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1724,"price":29.32,"value":50547.68,"ownership":{"direct":true},"balance_after":3445,"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860712,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:17:16.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":5169,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":5169,"source":{"system":"sec-edgar","filing":"0001193125-26-092074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092074/ownership.xml","form_type":"4"}},{"id":860711,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":9409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":28227,"derivative":{"underlying":"Common Stock","underlying_shares":9409},"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860710,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":35300,"derivative":{"underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860709,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":176550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":176550,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":176550},"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860708,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":3138,"price":29.32,"value":92006.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":13271,"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860707,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":9409,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":16409,"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860706,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:56:17.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":18357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":55071,"derivative":{"underlying":"Common Stock","underlying_shares":18357},"source":{"system":"sec-edgar","filing":"0001193125-26-092036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092036/ownership.xml","form_type":"4"}},{"id":860705,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:56:17.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":111900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":111900,"derivative":{"underlying":"Common Stock","underlying_shares":111900},"source":{"system":"sec-edgar","filing":"0001193125-26-092036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092036/ownership.xml","form_type":"4"}},{"id":860704,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:56:17.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":559600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":559600,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":559600},"source":{"system":"sec-edgar","filing":"0001193125-26-092036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092036/ownership.xml","form_type":"4"}},{"id":860703,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-04T23:56:17.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":7627,"price":29.32,"value":223623.64,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":33130,"source":{"system":"sec-edgar","filing":"0001193125-26-092036","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092036/ownership.xml","form_type":"4"}},{"id":860702,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-04T23:56:17.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":18357,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":40757,"source":{"system":"sec-edgar","filing":"0001193125-26-092036","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092036/ownership.xml","form_type":"4"}},{"id":860700,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":22055,"kind":"person","name":"Tripuraneni Radhika","position":1,"cik":"0001761114","reported_name":"Tripuraneni Radhika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:51:28.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":19150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":19150,"derivative":{"underlying":"Common Stock","underlying_shares":19150},"source":{"system":"sec-edgar","filing":"0001193125-26-092028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092028/ownership.xml","form_type":"4"}},{"id":860699,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":22055,"kind":"person","name":"Tripuraneni Radhika","position":1,"cik":"0001761114","reported_name":"Tripuraneni Radhika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:51:28.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":95800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":95800,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":95800},"source":{"system":"sec-edgar","filing":"0001193125-26-092028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092028/ownership.xml","form_type":"4"}},{"id":862181,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T19:15:18.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":6267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":18801,"derivative":{"underlying":"Common Stock","underlying_shares":6267},"source":{"system":"sec-edgar","filing":"0001193125-26-092071","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000119312526092071/ownership.xml","form_type":"4"}},{"id":862180,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T19:15:18.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":20550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":20550,"derivative":{"underlying":"Common Stock","underlying_shares":20550},"source":{"system":"sec-edgar","filing":"0001193125-26-092071","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000119312526092071/ownership.xml","form_type":"4"}},{"id":862179,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T19:15:18.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":102850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":102850,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":102850},"source":{"system":"sec-edgar","filing":"0001193125-26-092071","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000119312526092071/ownership.xml","form_type":"4"}},{"id":862178,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T19:15:18.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":2091,"price":29.32,"value":61308.12,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":7790,"source":{"system":"sec-edgar","filing":"0001193125-26-092071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000119312526092071/ownership.xml","form_type":"4"}},{"id":862177,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T19:15:18.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":6267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":9881,"source":{"system":"sec-edgar","filing":"0001193125-26-092071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000119312526092071/ownership.xml","form_type":"4"}},{"id":954882,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-02T22:25:52.000Z","date":"2025-12-31","kind":"sale","planned":false,"acquired":false,"shares":2272,"price":31.16,"value":70795.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares purchased under the Issuer's employee stock purchase plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-001097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526001097/ownership.xml","form_type":"4"}},{"id":1013103,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-27T20:30:38.000Z","date":"2025-10-23","kind":"purchase","planned":false,"acquired":true,"shares":454545,"price":22,"value":9999990.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") and Fairmount Healthcare Fund II GP LLC (\"Fairmount GP II\") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":3914458,"source":{"system":"sec-edgar","filing":"0001104659-25-102606","document":"tm2529526-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465925102606/tm2529526-1_4seq1.xml","form_type":"4"}},{"id":1095417,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32923,"kind":"person","name":"CAIN CHRISTOPHER W.","position":1,"cik":"0001817733","reported_name":"CAIN CHRISTOPHER W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:48:31.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817733/000095017025093118/ownership.xml","form_type":"4"}},{"id":1094270,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2224,"kind":"person","name":"Kiselak Tomas","position":1,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:46:45.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025093111/ownership.xml","form_type":"4"}},{"id":1094783,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":18365,"kind":"person","name":"Morris Arlene","position":1,"cik":"0001362520","reported_name":"Morris Arlene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:45:26.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362520/000095017025093107/ownership.xml","form_type":"4"}},{"id":1094362,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:43:44.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000095017025093102/ownership.xml","form_type":"4"}},{"id":1095612,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:43:25.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000095017025093099/ownership.xml","form_type":"4"}},{"id":1094265,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32643,"kind":"person","name":"Moses Jennifer K.","position":1,"cik":"0001706667","reported_name":"Moses Jennifer K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:43:01.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025093098/ownership.xml","form_type":"4"}},{"id":1114593,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:00:11.000Z","date":"2025-06-10","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":12.31,"exercise_date":"2023-06-08","expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-25-058580","document":"tm2517665d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465925058580/tm2517665d1_4seq1.xml","form_type":"4"}},{"id":1114592,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:00:11.000Z","date":"2025-06-09","kind":"exercise","planned":false,"acquired":false,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on October 27, 2020, the option vested monthly over a three-year period, subject to Peter Harwin's continued service to the Issuer. Mr. Harwin, a Managing Member of Fairmount and Fairmount GP II, served on the Issuer's Board of Directors through March 10, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":1600},"source":{"system":"sec-edgar","filing":"0001104659-25-058580","document":"tm2517665d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465925058580/tm2517665d1_4seq1.xml","form_type":"4"}},{"id":1114591,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:00:11.000Z","date":"2025-06-10","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":12.31,"value":153875.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") and Fairmount Healthcare Fund II GP LLC (\"Fairmount GP II\") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":3459913,"source":{"system":"sec-edgar","filing":"0001104659-25-058580","document":"tm2517665d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465925058580/tm2517665d1_4seq1.xml","form_type":"4"}},{"id":1114590,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:00:11.000Z","date":"2025-06-09","kind":"exercise","planned":false,"acquired":true,"shares":1600,"price":7.8,"value":12480.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") and Fairmount Healthcare Fund II GP LLC (\"Fairmount GP II\") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":3447413,"source":{"system":"sec-edgar","filing":"0001104659-25-058580","document":"tm2517665d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465925058580/tm2517665d1_4seq1.xml","form_type":"4"}},{"id":1174577,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-09T20:26:02.000Z","date":"2025-04-07","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":42000,"derivative":{"exercise_price":11.78,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-052530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000095017025052530/ownership.xml","form_type":"4"}},{"id":1209097,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":22055,"kind":"person","name":"Tripuraneni Radhika","position":1,"cik":"0001761114","reported_name":"Tripuraneni Radhika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-12T20:36:26.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":310700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on March 10, 2026 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":310700,"derivative":{"exercise_price":15.58,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":310700},"source":{"system":"sec-edgar","filing":"0000950170-25-038004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025038004/ownership.xml","form_type":"4"}},{"id":1209896,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32923,"kind":"person","name":"CAIN CHRISTOPHER W.","position":1,"cik":"0001817733","reported_name":"CAIN CHRISTOPHER W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-12T20:19:43.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":42000,"derivative":{"exercise_price":15.58,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-037965","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817733/000095017025037965/ownership.xml","form_type":"4"}},{"id":1226474,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-05T02:17:03.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":20679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":20679,"derivative":{"underlying":"Common Stock","underlying_shares":20679},"source":{"system":"sec-edgar","filing":"0000950170-25-032908","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032908/ownership.xml","form_type":"4"}},{"id":1226473,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T02:17:03.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":124072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 3, 2025."}],"balance_after":124072,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":124072},"source":{"system":"sec-edgar","filing":"0000950170-25-032908","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032908/ownership.xml","form_type":"4"}},{"id":1226470,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-05T02:14:09.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":73428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":73428,"derivative":{"underlying":"Common Stock","underlying_shares":73428},"source":{"system":"sec-edgar","filing":"0000950170-25-032891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032891/ownership.xml","form_type":"4"}},{"id":1226469,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T02:14:09.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":440565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 3, 2025."}],"balance_after":440565,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":440565},"source":{"system":"sec-edgar","filing":"0000950170-25-032891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032891/ownership.xml","form_type":"4"}},{"id":1226472,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-05T02:13:31.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":37636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":37636,"derivative":{"underlying":"Common Stock","underlying_shares":37636},"source":{"system":"sec-edgar","filing":"0000950170-25-032887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032887/ownership.xml","form_type":"4"}},{"id":1226471,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T02:13:31.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":225814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 3, 2025."}],"balance_after":225814,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":225814},"source":{"system":"sec-edgar","filing":"0000950170-25-032887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032887/ownership.xml","form_type":"4"}},{"id":1229765,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T21:12:50.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":25068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":25068,"derivative":{"underlying":"Common Stock","underlying_shares":25068},"source":{"system":"sec-edgar","filing":"0000950170-25-032884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000095017025032884/ownership.xml","form_type":"4"}},{"id":1229764,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:12:50.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":150407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 3, 2025."}],"balance_after":150407,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":150407},"source":{"system":"sec-edgar","filing":"0000950170-25-032884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000095017025032884/ownership.xml","form_type":"4"}},{"id":1397774,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-30T23:12:50.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":23.41,"value":117050.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on September 19, 2024 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000950170-24-110485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024110485/ownership.xml","form_type":"4"}},{"id":1397773,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-30T23:10:58.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":21400,"price":23.33,"value":499262.0,"ownership":{"direct":true},"balance_after":21400,"source":{"system":"sec-edgar","filing":"0000950170-24-110484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024110484/ownership.xml","form_type":"4"}},{"id":1404713,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":2,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T01:00:13.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":1600000,"price":18.75,"value":30000000.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":3445813,"source":{"system":"sec-edgar","filing":"0001104659-24-100769","document":"tm2424272-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000110465924100769/tm2424272-1_4seq1.xml","form_type":"4"}},{"id":1467346,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:25:36.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000095017024079084/ownership.xml","form_type":"4"}},{"id":1467116,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":18365,"kind":"person","name":"Morris Arlene","position":1,"cik":"0001362520","reported_name":"Morris Arlene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:05:08.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362520/000095017024079038/ownership.xml","form_type":"4"}},{"id":1466998,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32643,"kind":"person","name":"Moses Jennifer K.","position":1,"cik":"0001706667","reported_name":"Moses Jennifer K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:05:07.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024079037/ownership.xml","form_type":"4"}},{"id":1466997,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":1,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:05:06.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079044","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024079044/ownership.xml","form_type":"4"}},{"id":1466996,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2224,"kind":"person","name":"Kiselak Tomas","position":1,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:05:04.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079042","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024079042/ownership.xml","form_type":"4"}},{"id":1556370,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":21999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":133191,"derivative":{"underlying":"Common Stock","underlying_shares":1466673},"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556369,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":21999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1466673},"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556368,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":5859,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":1845813,"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556367,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":5859,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1642637,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":21164,"kind":"person","name":"Tousignant Jennifer","position":1,"cik":"0002010978","reported_name":"Tousignant Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T21:05:18.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":290000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on February 12, 2025 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":290000,"derivative":{"exercise_price":19.68,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0000950170-24-015205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024015205/ownership.xml","form_type":"4"}},{"id":1655423,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":94546,"kind":"person","name":"Ciulla Thomas","position":1,"cik":"0001815426","reported_name":"Ciulla Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-07T16:01:13.000Z","date":"2024-02-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 48 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":18.7,"expiration_date":"2034-02-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-012167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815426/000095017024012167/ownership.xml","form_type":"4"}},{"id":1672036,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-24T18:44:41.000Z","date":"2024-01-22","kind":"purchase","planned":false,"acquired":true,"shares":476190,"price":21,"value":9999990.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":1839954,"source":{"system":"sec-edgar","filing":"0000950170-24-007123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024007123/ownership.xml","form_type":"4"}},{"id":1744303,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":62053,"kind":"person","name":"Harmon Seth","position":1,"cik":"0001993300","reported_name":"Harmon Seth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-13T17:17:05.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":270000,"derivative":{"exercise_price":13.76,"expiration_date":"2033-11-10","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0000950170-23-063124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1993300/000095017023063124/ownership.xml","form_type":"4"}},{"id":1752469,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2023-11-01T21:05:00.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":48463,"price":825.3746,"value":40000129.2398,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B non-voting convertible preferred stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and Series B non-voting convertible preferred stock held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":48463,"derivative":{"underlying":"Common Stock","underlying_shares":3231028.21},"source":{"system":"sec-edgar","filing":"0000950170-23-057692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023057692/ownership.xml","form_type":"4"}},{"id":1752357,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T20:35:05.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":474400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on October 30, 2024 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":474400,"derivative":{"exercise_price":13.02,"expiration_date":"2023-10-30","underlying":"Common Stock","underlying_shares":474400},"source":{"system":"sec-edgar","filing":"0000950170-23-057520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017023057520/ownership.xml","form_type":"4"}},{"id":1752356,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61971,"kind":"person","name":"Mahoney Stephen F.","position":1,"cik":"0001741389","reported_name":"Mahoney Stephen F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T20:35:03.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":1259400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on October 30, 2024 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":1259400,"derivative":{"exercise_price":13.02,"expiration_date":"2033-10-30","underlying":"Common Stock","underlying_shares":1259400},"source":{"system":"sec-edgar","filing":"0000950170-23-057519","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017023057519/ownership.xml","form_type":"4"}},{"id":1774045,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-25T20:35:04.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":15.74,"expiration_date":"2033-09-21","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-23-049704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000095017023049704/ownership.xml","form_type":"4"}},{"id":1850579,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":false,"shares":28,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":37453,"derivative":{"exercise_price":23.03,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":28},"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850578,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":false,"shares":2269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":37481,"derivative":{"exercise_price":23.03,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":2269},"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850577,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":27,"price":28.35,"value":765.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to the Plan."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850576,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":true,"shares":27,"price":23.03,"value":621.81,"ownership":{"direct":true},"balance_after":29998,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850575,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":2269,"price":28.02,"value":63577.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850574,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":true,"shares":2269,"price":23.03,"value":52255.07,"ownership":{"direct":true},"balance_after":32240,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1851373,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":1,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-17T00:00:12.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC  (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":20000,"derivative":{"exercise_price":27.67,"expiration_date":"2023-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-028727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017023028727/ownership.xml","form_type":"4"}},{"id":1851372,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32643,"kind":"person","name":"Moses Jennifer K.","position":1,"cik":"0001706667","reported_name":"Moses Jennifer K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:54:28.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-028725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017023028725/ownership.xml","form_type":"4"}},{"id":1851371,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2224,"kind":"person","name":"Kiselak Tomas","position":1,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:54:24.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Fairmount Funds Management LLC  (the \"Adviser\"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":20000,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-028724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017023028724/ownership.xml","form_type":"4"}},{"id":1851898,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":18365,"kind":"person","name":"Morris Arlene","position":1,"cik":"0001362520","reported_name":"Morris Arlene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:51:24.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-028721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362520/000095017023028721/ownership.xml","form_type":"4"}},{"id":1865674,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-06","kind":"exercise","planned":true,"acquired":false,"shares":5126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":84375,"derivative":{"exercise_price":18.51,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":5126},"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865673,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-05","kind":"exercise","planned":true,"acquired":false,"shares":499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":89501,"derivative":{"exercise_price":18.51,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":499},"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865672,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-02","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":18128,"derivative":{"exercise_price":14,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865671,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-06","kind":"sale","planned":true,"acquired":false,"shares":5126,"price":25.02,"value":128252.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865670,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-06","kind":"exercise","planned":true,"acquired":true,"shares":5126,"price":18.51,"value":94882.26,"ownership":{"direct":true},"balance_after":35097,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865669,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-05","kind":"sale","planned":true,"acquired":false,"shares":499,"price":25.03,"value":12489.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865668,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-05","kind":"exercise","planned":true,"acquired":true,"shares":499,"price":18.51,"value":9236.49,"ownership":{"direct":true},"balance_after":30470,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865667,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-02","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":24.21,"value":45393.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}}],"next_cursor":"2023-06-06T23:41:29.000000Z,1865667"}